海正生材12月29日获融资买入104.64万元，融资余额5049.86万元

Core Viewpoint - The financial performance of Zhejiang Haizheng Biomaterials Co., Ltd. shows a decline in revenue and net profit, indicating potential challenges in the company's operations and market conditions [2]. Group 1: Financial Performance - As of September 30, 2025, Haizheng Biomaterials reported a revenue of 621 million yuan, a year-on-year decrease of 5.74% [2]. - The net profit attributable to the parent company was 4.91 million yuan, reflecting a significant year-on-year decline of 85.34% [2]. - Cumulative cash dividends since the company's A-share listing amount to 42.49 million yuan [2]. Group 2: Shareholder and Market Activity - The number of shareholders as of September 30, 2025, was 6,695, a decrease of 10.22% from the previous period [2]. - The average number of circulating shares per shareholder increased by 17.43% to 18,538 shares [2]. - The financing balance of Haizheng Biomaterials reached 50.50 million yuan, accounting for 3.17% of the market capitalization, indicating a high level of financing activity [1].